<![CDATA[Why a Gentler AML Regimen Outperforming Chemotherapy Matters]]>

Data Readoutpositiveazacitidine/venetoclaxPositive

AI Analysis

Summary

Azacitidine/venetoclax demonstrated improved event-free survival over chemotherapy in fit patients with acute myeloid leukemia, according to expert commentary from Dr. Amir T. Fathi.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Azacitidine/venetoclax demonstrated improved event-free survival (EFS) over chemotherapy in fit patients with AML

Importance:6/10

Sentiment:

0.75

AMLazacitidinevenetoclaxclinical trialEFSchemotherapy comparison

Related Companies

$CELG

Read the original article

Published by Cancer Network on September 15, 2026 12:00 PM

Read Original